NCT06779097View on ClinicalTrials.gov

Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

1,564

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

February 29, 2028

Conditions
Moderate to Severe Plaque Psoriasis
Interventions
DRUG

Vunakizumab (IL-17A inhibitor)

Vunakizumab (IL-17A inhibitor)

Trial Locations (1)

100029

China-Japan Friendship Hospital, Beijing

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT06779097 - Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter